Injectable Gel: A New Frontier in Cancer Immunotherapy
Researchers from MIT and Massachusetts General Hospital (MGH) have developed a
novel platform that could revolutionize cancer immunotherapy by delivering
treatments directly into tumors in a more efficient, targeted, and lasting
way. This innovation involves a thermosensitive gel made from safe,
biocompatible polymers that solidify inside tumors, enabling a controlled
release of FDA-approved immunotherapies like imiquimod over several days.
Tested in mouse models for colon and breast cancer, the treatment achieved significant results when combined with checkpoint blockade therapy, showing potential for inducing the abscopal effect—where both treated and untreated tumors regress.
The gel’s design incorporates imaging agents for accurate delivery using CT or ultrasound, addressing a critical challenge in intratumoral immunotherapy. This approach reduces the need for repeated injections, cutting costs and enhancing feasibility in clinical settings. Future developments may adapt this platform to treat other tumor types or carry additional therapies, accelerating its path to FDA approval due to its use of existing drugs and materials
No Comment to " Injectable Gel: A New Frontier in Cancer Immunotherapy "